Carolyn Anderson View Appointment Options Carolyn Anderson Appointment Options Research & Selected Publications Share Copy Link Email Link Print Page Facebook X Instagram LinkedIn Back Gmail Outlook Apple Mail Yahoo! Mail Appointment Options Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you. Request an Appointment Call Us Refer a Patient Research & Selected Publications Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer Development of an automated one-step radiolabeling procedure for a PSMA-targeted radiotherapeutic for prostate cancer Authors: Ocak M, Sikligar K, Pun M, [...]one or more additional authors omitted Anderson CJ Journal & Year: Nucl Med Biol | 2026 Matched pair suitability of 89Zr and 177Lu-labeled L804-LLP2A theranostics for targeting VLA-4 in melanoma Matched pair suitability of 89Zr and 177Lu-labeled L804-LLP2A theranostics for targeting VLA-4 in melanoma Authors: Fong COY, Iweha EV, Gallazzi F, [...]one or more additional authors omitted Anderson CJ Journal & Year: Nucl Med Biol | 2026 Effect of Click Chemistry Linkages on the Biological Behavior of Albumin-Binding 177Lu-DOTAGA-pIBA-LLP2A Analogues Targeting Melanoma Effect of Click Chemistry Linkages on the Biological Behavior of Albumin-Binding 177Lu-DOTAGA-pIBA-LLP2A Analogues Targeting Melanoma Authors: Li L, Wirrick A, Pun MD, [...]one or more additional authors omitted Anderson CJ Journal & Year: Bioconjug Chem | 2025 Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer Authors: Ho KV, Tatum DS, Watkinson L, [...]one or more additional authors omitted Anderson CJ Journal & Year: J Nucl Med | 2024 Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma Authors: Pun MD, Gallazzi F, Ho KV, [...]one or more additional authors omitted Anderson CJ Journal & Year: Mol Pharm | 2024
